Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(40.0%)
Phase 2
2(40.0%)
Phase 1
1(20.0%)
5Total
Phase 3(2)
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04744402Phase 2Unknown

Phase 2 Clinical Trial of CartiLife® in the United States

Role: lead

NCT05051332Phase 3Unknown

Phase 3 Clinical Trial of CartiLife® in Korea

Role: lead

NCT03545269Phase 2Completed

Study to Assess the Efficacy and Safety of Treatment of Articular Cartilage Lesions With CartiLife®

Role: lead

NCT03517046Phase 1Completed

Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®

Role: lead

NCT00978705Phase 3Unknown

Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood

Role: lead

All 5 trials loaded